Answers are grounded in this paper and cite their sources.
// Rui Wang 1,* , Dong-Qin Chen 1,* , Jia-Yuan Huang 1 , Kai Zhang 1 , Bing Feng 1 , Ban-Zhou Pan 1 , Jing Chen 1 , Wei De 2 , Long-Bang Chen 1 1 Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210002, China 2 Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu 210002, China * Co-first authors Correspondence: Long-Bang Chen, email: // Keywords : lung adenocarcinoma, chemoresistance, radioresistance, miR-451, c-Myc, rad-51, survivin Received : May 26, 2014 Accepted : July 05, 2014 Published : July 07, 2014 Abstract Chemoresistant tumors usually fail to respond to radiotherapy. However, the mechanisms involved in chemo- and radiotherapy cross resistance are not fully understood. Previously, we have identified microRNA (miR)-451 as a tumor suppressor in lung adenocarcinoma (LAD). However, whether miR-451 plays critical roles in chemo- and radiotherapy cross resistance in LAD is unclear. Here, we established two docetaxel-resistant LAD cell models (SPC-A1/DTX and H1299/DTX), and showed that miR-451 was significantly downregulated in docetaxel-resistant LAD cells. Gain - and loss - of - function assays indicated that re-expression of miR-451 could reverse radioresistance of docetaxel-resistant LAD cells both in vitro and in vivo through promoting apoptosis and DNA double-strand breaks (DSBs). The proto-oncogene c-Myc was identified as a direct target of miR-451, and re-expression of miR-451 inhibited survivin and rad-51 expression by reducing the amount of c-Myc protein binding to their promoters. Silencing of c-Myc could phenocopy the effects of miR-451 upregulation, and restoration of c-Myc could partially rescue the effect of miR-451 upregulation on radiosensitivity of docetaxel-resistant LAD cells. Therefore, dysregulation of miR-451/c-Myc-survivin/rad-51 signaling is responsible for radioresistance of docetaxel-resistant LAD cells, and targeting it will be a potential strategy for reversing chemo- and radiotherapy cross resistance of LAD patients.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: